4.6 Article

Ganoderma lucidum enhances carboplatin chemotherapy effect by inhibiting the DNA damage response pathway and stemness

期刊

AMERICAN JOURNAL OF CANCER RESEARCH
卷 12, 期 3, 页码 1282-1294

出版社

E-CENTURY PUBLISHING CORP

关键词

Inflammatory breast cancer; Ganoderma lucidum; cancer stem cells; DNA damage response; Reishi; ATM; ATR; Chk1; Chk2; tumor

类别

资金

  1. National Institutes of Health [SC3GM111171, U54GM133807, R25GM110513]
  2. NIH [R01CA207893, R01-CA178509]
  3. Breast Cancer Research Foundation [BCRF-20-146]
  4. PR-INBRE [P20GM103475]
  5. Title-V-Cooperative [P031S130068]

向作者/读者索取更多资源

This study investigates the therapeutic potential of using medicinal mushroom Ganoderma lucidum (GLE) in combination with carboplatin for the treatment of Inflammatory Breast Cancer (IBC). The results show that the GLE/carboplatin combination reduces cell viability, induces cell death through two different mechanisms, and delays the response to DNA damage. In addition, the combination treatment suppresses mammosphere formation and the expression of cancer stemness proteins. In animal models, the combination treatment exhibits significant tumor growth inhibitory effects without systemic toxicity.
Inflammatory Breast Cancer (IBC) is a rare and aggressive type of breast cancer with a poor prognosis. Its management is challenging because of a lack of targeted therapies, increased metastatic potential, and high recurrence rates. Interest in using platinum agents such as carboplatin emerged from data suggesting frequent DNA repair defects in breast cancer. Because studies show that medicinal mushroom Ganoderma lucidum (GLE) sensitizes cancer cells to radiation and other drugs; herein, we aimed to investigate the therapeutic potential of GLE, alone or in combination with carboplatin in breast cancer models. Our studies were focused on the regulation of the DNA Damage Response (DDR) and on cancer cell sternness. Carboplatin and GLE were tested in vitro using the IBC cell line, SUM-149, breast cancer non-IBC cells, MDA-MB-231, and in vivo using IBC xenograft models. Our results show that the GLE/carboplatin combination decreased cell viability, induced cell death by two different mechanisms, and delayed the response to DNA damage. Furthermore, the combination suppressed mammosphere formation and the expression of cancer stemness proteins. In xenograft models, the combination showed significant tumor growth inhibitory effects without systemic toxicity. This study emphasizes the potential of this dual therapy for IBC patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据